<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072237</url>
  </required_header>
  <id_info>
    <org_study_id>MAA-102</org_study_id>
    <nct_id>NCT04072237</nct_id>
  </id_info>
  <brief_title>Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia</brief_title>
  <official_title>Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalyst Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalyst Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, open label Phase 1 study will evaluate the pharmacokinetics,&#xD;
      pharmacodynamics, and safety of a single IV dose of MarzAA followed by ascending single SC&#xD;
      doses of MarzAA in adult subjects with moderate or severe Hemophilia A or B, with or without&#xD;
      an inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, open label Phase 1 study will evaluate the pharmacokinetics,&#xD;
      pharmacodynamics, and safety of a single IV dose of MarzAA followed by ascending single SC&#xD;
      doses of MarzAA in adult subjects with moderate or severe Hemophilia A or B, with or without&#xD;
      an inhibitor. The study will enroll at least 8 adult male subjects with moderate or severe&#xD;
      Hemophilia A or B with or without an inhibitor, in each dosing stage. Each subject will&#xD;
      receive escalating doses of MarzAA for each stage of the study (except for Stage 5, where&#xD;
      subjects receive the same dose as in Stage 4 split between two anatomical sites).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Actual">June 17, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Comparative pharmacokinetics (PK) by dose level/stage based on examination of AUC frequencies of these for each of the dose groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparative MarzAA Activity by Dose Level/Stage - AUCT1-T2 Normalized by Dose = AUC0-last/Dose</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Comparative pharmacokinetics by dose level/stage based on examination of AUC frequency of these for each of the dose groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - Cmax</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in Cmax at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - Tmax</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in Tmax at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2eqα</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in T1/2eqα at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2λ-z</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in T1/2λ-z at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - CL</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in CL at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - Vd1</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in Vd1 at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - BAabs</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in BAabs at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative MarzAA Activity of Intravenous and Subcutaneous - Mean Residence Time</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>Change in Mean Residence Time at each stage for each dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC From T1 to T2 Norm by Dose</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC Infinity Obs and AUC to Last Nonzero Conc</measure>
    <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
    <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters - Prothrombin Time (PT)</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-7 (SC).</time_frame>
    <description>Maximum change in PT from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters - Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in aPTT from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Peak</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in TGT parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Lag and TGT-Time to Peak</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in TGT parameters from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Endogenous Thrombin Potential</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in TGT parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombogenicity Parameter - Fibrinogen</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in thrombogenicity parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombogenicity Parameter - Prothrombin Fragments 1 + 2</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in thrombogenicity parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombogenicity Parameter - Thrombin/Antithrombin</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in thrombogenicity parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombogenicity Parameter - D-Dimer</measure>
    <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
    <description>Maximum change in thrombogenicity parameter from pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of an Antibody Response to MarzAA</measure>
    <time_frame>From time of first dose of MarzAA until date of first occurrence of clinical event, assessed up to End of Study. Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing.</time_frame>
    <description>Occurrence of an antibody response to MarzAA and whether it is inhibitory and cross-reactive to wild-type recombinant coagulation FVII (wt-rFVII) or wt-FVIIa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clinical Thrombotic Event</measure>
    <time_frame>From the date of first dose of MarzAA until date of first occurrence of clinical event, assessed up to End of Study. Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing.</time_frame>
    <description>Occurrence of clinical thrombotic event not attributable to another cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia B With Inhibitor</condition>
  <condition>Hemophilia A Without Inhibitor</condition>
  <condition>Hemophilia B Without Inhibitor</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MarzAA (marzeptacog alfa [activated])</intervention_name>
    <description>Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)</description>
    <arm_group_label>Study Population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate or severe congenital Hemophilia A or B, with or without an inhibitor&#xD;
&#xD;
          -  Male, age 18 or older&#xD;
&#xD;
          -  Affirmation of informed consent with signature confirmation before any trial related&#xD;
             activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to discontinue and washout prophylaxis treatment 72 hours prior to dosing.&#xD;
&#xD;
          -  Previous participation in a trial involving SC Administration of rFVIIa or any trial&#xD;
             using a modified amino-acid sequence FVIIa&#xD;
&#xD;
          -  Known positive antibody to FVII or FVIIa detected by central laboratory at screening&#xD;
&#xD;
          -  Have a coagulation disorder other than hemophilia A or B, with or without an inhibitor&#xD;
&#xD;
          -  Significant contraindication to participate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Levy, MD, PhD, MMM</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center &quot;Hippocrates - N&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Hematology Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Policlinic # 37, City Center for Hemophilia Treatment</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is an open label study so each investigator will have full access to all study subject data that is entered into the database.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04072237/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Fourteen subjects were screened in the study and three subjects were screen failures. Two subjects failed due to having a known positive antibody at screening, and one subject failed screening due to other.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study Population</title>
          <description>Coagulation Factor VIIa variant: Single intravenous dose and ascending doses of subcutaneous injection of MarzAA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage I: MarzAA 18 µg/kg IV</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2: MarzAA 30 µg/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 3: MarzAA 45 µg/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 4: MarzAA 60 µg/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 5: MarzAA 2 x 30 ug/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 6: MarzAA 90 µg/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 7: MarzAA 120 µg/kg SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 8: MarzAA 2 x 60 µg/kg Q3H SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 9: MarzAA 3 x 60 µg/kg Q3H SC</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Population</title>
          <description>MarzAA (Marzeptacog Alfa [activated], Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last</title>
        <description>Comparative pharmacokinetics (PK) by dose level/stage based on examination of AUC frequencies of these for each of the dose groups</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last</title>
          <description>Comparative pharmacokinetics (PK) by dose level/stage based on examination of AUC frequencies of these for each of the dose groups</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1390.0" spread="433.99"/>
                    <measurement group_id="O2" value="516.4" spread="170.01"/>
                    <measurement group_id="O3" value="849.4" spread="275.00"/>
                    <measurement group_id="O4" value="1060.0" spread="205.86"/>
                    <measurement group_id="O5" value="1025.6" spread="328.31"/>
                    <measurement group_id="O6" value="1487.9" spread="429.39"/>
                    <measurement group_id="O7" value="2087.6" spread="648.85"/>
                    <measurement group_id="O8" value="2108.0" spread="409.00"/>
                    <measurement group_id="O9" value="3235.5" spread="735.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-last</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1382.6" spread="431.45"/>
                    <measurement group_id="O2" value="429.5" spread="178.30"/>
                    <measurement group_id="O3" value="692.9" spread="232.53"/>
                    <measurement group_id="O4" value="922.1" spread="192.38"/>
                    <measurement group_id="O5" value="934.1" spread="305.32"/>
                    <measurement group_id="O6" value="1322.6" spread="440.03"/>
                    <measurement group_id="O7" value="1868.1" spread="651.04"/>
                    <measurement group_id="O8" value="1939.1" spread="357.25"/>
                    <measurement group_id="O9" value="3038.1" spread="760.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparative MarzAA Activity by Dose Level/Stage - AUCT1-T2 Normalized by Dose = AUC0-last/Dose</title>
        <description>Comparative pharmacokinetics by dose level/stage based on examination of AUC frequency of these for each of the dose groups</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity by Dose Level/Stage - AUCT1-T2 Normalized by Dose = AUC0-last/Dose</title>
          <description>Comparative pharmacokinetics by dose level/stage based on examination of AUC frequency of these for each of the dose groups</description>
          <units>h*kg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.81" spread="23.97"/>
                    <measurement group_id="O2" value="14.32" spread="5.94"/>
                    <measurement group_id="O3" value="15.40" spread="5.17"/>
                    <measurement group_id="O4" value="15.37" spread="3.206"/>
                    <measurement group_id="O5" value="15.57" spread="5.09"/>
                    <measurement group_id="O6" value="14.70" spread="4.89"/>
                    <measurement group_id="O7" value="15.57" spread="5.43"/>
                    <measurement group_id="O8" value="16.16" spread="2.98"/>
                    <measurement group_id="O9" value="16.88" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Cmax</title>
        <description>Change in Cmax at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Cmax</title>
          <description>Change in Cmax at each stage for each dose group</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.49" spread="185.18"/>
                    <measurement group_id="O2" value="18.96" spread="10.29"/>
                    <measurement group_id="O3" value="32.91" spread="18.49"/>
                    <measurement group_id="O4" value="41.88" spread="15.24"/>
                    <measurement group_id="O5" value="40.75" spread="15.98"/>
                    <measurement group_id="O6" value="54.29" spread="24.68"/>
                    <measurement group_id="O7" value="76.70" spread="34.51"/>
                    <measurement group_id="O8" value="68.04" spread="26.58"/>
                    <measurement group_id="O9" value="98.33" spread="32.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Tmax</title>
        <description>Change in Tmax at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Tmax</title>
          <description>Change in Tmax at each stage for each dose group</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.29"/>
                    <measurement group_id="O2" value="7.50" spread="1.60"/>
                    <measurement group_id="O3" value="7.38" spread="2.56"/>
                    <measurement group_id="O4" value="8.25" spread="1.39"/>
                    <measurement group_id="O5" value="6.75" spread="1.398"/>
                    <measurement group_id="O6" value="7.12" spread="1.55"/>
                    <measurement group_id="O7" value="8.25" spread="1.39"/>
                    <measurement group_id="O8" value="8.37" spread="2.67"/>
                    <measurement group_id="O9" value="12.25" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2eqα</title>
        <description>Change in T1/2eqα at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2eqα</title>
          <description>Change in T1/2eqα at each stage for each dose group</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.55"/>
                    <measurement group_id="O2" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                    <measurement group_id="O9" value="NA" spread="NA">T1/2eqα was measured and derived only at IV dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2λ-z</title>
        <description>Change in T1/2λ-z at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2λ-z</title>
          <description>Change in T1/2λ-z at each stage for each dose group</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.38"/>
                    <measurement group_id="O2" value="18.55" spread="5.88"/>
                    <measurement group_id="O3" value="19.26" spread="6.69"/>
                    <measurement group_id="O4" value="15.70" spread="3.45"/>
                    <measurement group_id="O5" value="13.05" spread="5.07"/>
                    <measurement group_id="O6" value="15.50" spread="5.65"/>
                    <measurement group_id="O7" value="15.03" spread="4.43"/>
                    <measurement group_id="O8" value="18.82" spread="5.82"/>
                    <measurement group_id="O9" value="18.07" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - CL</title>
        <description>Change in CL at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - CL</title>
          <description>Change in CL at each stage for each dose group</description>
          <units>mL/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.22" spread="4.66"/>
                    <measurement group_id="O2" value="63.33" spread="19.64"/>
                    <measurement group_id="O3" value="57.85" spread="18.21"/>
                    <measurement group_id="O4" value="58.88" spread="13.68"/>
                    <measurement group_id="O5" value="63.92" spread="20.36"/>
                    <measurement group_id="O6" value="65.13" spread="18.67"/>
                    <measurement group_id="O7" value="64.39" spread="26.93"/>
                    <measurement group_id="O8" value="59.05" spread="12.68"/>
                    <measurement group_id="O9" value="58.22" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Vd1</title>
        <description>Change in Vd1 at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Vd1</title>
          <description>Change in Vd1 at each stage for each dose group</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.41" spread="18.02"/>
                    <measurement group_id="O2" value="1868.28" spread="962.02"/>
                    <measurement group_id="O3" value="1651.05" spread="799.32"/>
                    <measurement group_id="O4" value="1400.41" spread="478.92"/>
                    <measurement group_id="O5" value="1344.19" spread="557.26"/>
                    <measurement group_id="O6" value="1577.63" spread="791.28"/>
                    <measurement group_id="O7" value="1509.24" spread="796.50"/>
                    <measurement group_id="O8" value="1699.49" spread="474.39"/>
                    <measurement group_id="O9" value="1717.33" spread="629.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - BAabs</title>
        <description>Change in BAabs at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - BAabs</title>
          <description>Change in BAabs at each stage for each dose group</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="100"/>
                    <measurement group_id="O2" value="19.47" spread="8.07"/>
                    <measurement group_id="O3" value="21.52" spread="10.63"/>
                    <measurement group_id="O4" value="21.32" spread="7.42"/>
                    <measurement group_id="O5" value="20.87" spread="6.32"/>
                    <measurement group_id="O6" value="19.84" spread="7.20"/>
                    <measurement group_id="O7" value="21.24" spread="9.32"/>
                    <measurement group_id="O8" value="23.00" spread="8.98"/>
                    <measurement group_id="O9" value="23.32" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Mean Residence Time</title>
        <description>Change in Mean Residence Time at each stage for each dose group</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative MarzAA Activity of Intravenous and Subcutaneous - Mean Residence Time</title>
          <description>Change in Mean Residence Time at each stage for each dose group</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.42"/>
                    <measurement group_id="O2" value="28.25" spread="9.18"/>
                    <measurement group_id="O3" value="28.10" spread="9.94"/>
                    <measurement group_id="O4" value="23.79" spread="5.40"/>
                    <measurement group_id="O5" value="20.96" spread="5.58"/>
                    <measurement group_id="O6" value="23.42" spread="7.47"/>
                    <measurement group_id="O7" value="22.80" spread="5.9211"/>
                    <measurement group_id="O8" value="29.04" spread="7.88"/>
                    <measurement group_id="O9" value="29.32" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC From T1 to T2 Norm by Dose</title>
        <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 4 MarzAA 60μg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 5 MarzAA 2×30μg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC From T1 to T2 Norm by Dose</title>
          <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
          <units>h*kg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3687" spread="3.20630"/>
                    <measurement group_id="O2" value="15.5688" spread="5.08859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC Infinity Obs and AUC to Last Nonzero Conc</title>
        <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
        <time_frame>Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing, depending on participation in all 9 stages and time elapsed between each study stage.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 4 MarzAA 60μg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 5 MarzAA 2×30μg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA coagulation factor VIIa variant</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC Infinity Obs and AUC to Last Nonzero Conc</title>
          <description>PK analysis by route of administration, dose level/stage of the study based on examination of AUC for each of the dose groups.&#xD;
Split dose (2*30 µg/kg) vs. (60 µg/kg)</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC Infinity Obs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060.0" spread="205.86"/>
                    <measurement group_id="O2" value="1025.6" spread="328.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC to Last Nonzero Conc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="922.1" spread="192.38"/>
                    <measurement group_id="O2" value="934.1" spread="305.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coagulation Parameters - Prothrombin Time (PT)</title>
        <description>Maximum change in PT from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-7 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg SC</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coagulation Parameters - Prothrombin Time (PT)</title>
          <description>Maximum change in PT from pre-dose</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.57"/>
                    <measurement group_id="O2" value="-1.41" spread="0.86"/>
                    <measurement group_id="O3" value="-1.16" spread="0.68"/>
                    <measurement group_id="O4" value="-1.09" spread="0.58"/>
                    <measurement group_id="O5" value="-1.29" spread="0.86"/>
                    <measurement group_id="O6" value="-1.07" spread="0.79"/>
                    <measurement group_id="O7" value="-1.37" spread="0.54"/>
                    <measurement group_id="O8" value="-1.36" spread="0.60"/>
                    <measurement group_id="O9" value="-1.35" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coagulation Parameters - Activated Partial Thromboplastin Time (aPTT)</title>
        <description>Maximum change in aPTT from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg SC</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coagulation Parameters - Activated Partial Thromboplastin Time (aPTT)</title>
          <description>Maximum change in aPTT from pre-dose</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" spread="3.71"/>
                    <measurement group_id="O2" value="1.91" spread="3.21"/>
                    <measurement group_id="O3" value="-2.33" spread="4.28"/>
                    <measurement group_id="O4" value="-2.18" spread="2.63"/>
                    <measurement group_id="O5" value="-2.51" spread="2.09"/>
                    <measurement group_id="O6" value="-2.85" spread="1.82"/>
                    <measurement group_id="O7" value="-2.10" spread="3.02"/>
                    <measurement group_id="O8" value="-2.92" spread="3.01"/>
                    <measurement group_id="O9" value="-5.13" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Peak</title>
        <description>Maximum change in TGT parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Peak</title>
          <description>Maximum change in TGT parameter from pre-dose</description>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="65.32"/>
                    <measurement group_id="O2" value="14.9" spread="31.69"/>
                    <measurement group_id="O3" value="28.3" spread="21.04"/>
                    <measurement group_id="O4" value="42.3" spread="32.13"/>
                    <measurement group_id="O5" value="45.4" spread="30.84"/>
                    <measurement group_id="O6" value="33.0" spread="25.16"/>
                    <measurement group_id="O7" value="44.3" spread="46.10"/>
                    <measurement group_id="O8" value="45.6" spread="19.18"/>
                    <measurement group_id="O9" value="41.3" spread="30.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Lag and TGT-Time to Peak</title>
        <description>Maximum change in TGT parameters from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two single subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Lag and TGT-Time to Peak</title>
          <description>Maximum change in TGT parameters from pre-dose</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TGT-Lag</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.231"/>
                    <measurement group_id="O2" value="-1.21" spread="0.613"/>
                    <measurement group_id="O3" value="-1.11" spread="0.391"/>
                    <measurement group_id="O4" value="-1.42" spread="0.645"/>
                    <measurement group_id="O5" value="-1.38" spread="0.311"/>
                    <measurement group_id="O6" value="-1.07" spread="0.655"/>
                    <measurement group_id="O7" value="-1.33" spread="0.396"/>
                    <measurement group_id="O8" value="-1.54" spread="0.507"/>
                    <measurement group_id="O9" value="-1.13" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGT-Time to Peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.88" spread="3.302"/>
                    <measurement group_id="O2" value="-2.22" spread="2.309"/>
                    <measurement group_id="O3" value="-2.76" spread="1.226"/>
                    <measurement group_id="O4" value="-3.53" spread="2.313"/>
                    <measurement group_id="O5" value="-3.68" spread="1.290"/>
                    <measurement group_id="O6" value="-3.73" spread="1.926"/>
                    <measurement group_id="O7" value="-3.73" spread="2.024"/>
                    <measurement group_id="O8" value="-3.70" spread="1.681"/>
                    <measurement group_id="O9" value="-3.25" spread="1.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Endogenous Thrombin Potential</title>
        <description>Maximum change in TGT parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Endogenous Thrombin Potential</title>
          <description>Maximum change in TGT parameter from pre-dose</description>
          <units>nM•minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.9" spread="337.55"/>
                    <measurement group_id="O2" value="158.6" spread="247.55"/>
                    <measurement group_id="O3" value="94.3" spread="148.51"/>
                    <measurement group_id="O4" value="149.5" spread="256.34"/>
                    <measurement group_id="O5" value="211.0" spread="190.22"/>
                    <measurement group_id="O6" value="133.0" spread="193.85"/>
                    <measurement group_id="O7" value="216.9" spread="184.54"/>
                    <measurement group_id="O8" value="164.6" spread="58.49"/>
                    <measurement group_id="O9" value="-187.3" spread="474.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombogenicity Parameter - Fibrinogen</title>
        <description>Maximum change in thrombogenicity parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombogenicity Parameter - Fibrinogen</title>
          <description>Maximum change in thrombogenicity parameter from pre-dose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" spread="23.83"/>
                    <measurement group_id="O2" value="13.3" spread="29.65"/>
                    <measurement group_id="O3" value="-23.6" spread="34.04"/>
                    <measurement group_id="O4" value="16.0" spread="37.67"/>
                    <measurement group_id="O5" value="7.6" spread="51.69"/>
                    <measurement group_id="O6" value="-31.0" spread="42.02"/>
                    <measurement group_id="O7" value="21.6" spread="56.61"/>
                    <measurement group_id="O8" value="-12.5" spread="32.74"/>
                    <measurement group_id="O9" value="-8.0" spread="33.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombogenicity Parameter - Prothrombin Fragments 1 + 2</title>
        <description>Maximum change in thrombogenicity parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombogenicity Parameter - Prothrombin Fragments 1 + 2</title>
          <description>Maximum change in thrombogenicity parameter from pre-dose</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1903.5" spread="3809.47"/>
                    <measurement group_id="O2" value="206.3" spread="545.97"/>
                    <measurement group_id="O3" value="56.0" spread="158.02"/>
                    <measurement group_id="O4" value="76.5" spread="118.78"/>
                    <measurement group_id="O5" value="383.9" spread="324.41"/>
                    <measurement group_id="O6" value="974.5" spread="2407.09"/>
                    <measurement group_id="O7" value="1744.9" spread="4367.48"/>
                    <measurement group_id="O8" value="236.5" spread="459.58"/>
                    <measurement group_id="O9" value="284.9" spread="672.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombogenicity Parameter - Thrombin/Antithrombin</title>
        <description>Maximum change in thrombogenicity parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombogenicity Parameter - Thrombin/Antithrombin</title>
          <description>Maximum change in thrombogenicity parameter from pre-dose</description>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.09" spread="254.951"/>
                    <measurement group_id="O2" value="62.34" spread="156.899"/>
                    <measurement group_id="O3" value="10.41" spread="19.586"/>
                    <measurement group_id="O4" value="63.57" spread="181.409"/>
                    <measurement group_id="O5" value="138.19" spread="202.946"/>
                    <measurement group_id="O6" value="56.79" spread="146.603"/>
                    <measurement group_id="O7" value="10.46" spread="15.648"/>
                    <measurement group_id="O8" value="18.90" spread="38.191"/>
                    <measurement group_id="O9" value="3.75" spread="3.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombogenicity Parameter - D-Dimer</title>
        <description>Maximum change in thrombogenicity parameter from pre-dose</description>
        <time_frame>From predose to Day 2 at stage 1 (IV). From predose to Day 3 at stages 2-9 (SC).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombogenicity Parameter - D-Dimer</title>
          <description>Maximum change in thrombogenicity parameter from pre-dose</description>
          <units>mg/L Fibrinogen Equivalent Unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.141" spread="0.214"/>
                    <measurement group_id="O2" value="-0.054" spread="0.104"/>
                    <measurement group_id="O3" value="0.110" spread="0.080"/>
                    <measurement group_id="O4" value="0.039" spread="0.073"/>
                    <measurement group_id="O5" value="0.285" spread="0.605"/>
                    <measurement group_id="O6" value="0.200" spread="0.175"/>
                    <measurement group_id="O7" value="0.211" spread="0.285"/>
                    <measurement group_id="O8" value="0.111" spread="0.125"/>
                    <measurement group_id="O9" value="0.256" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of an Antibody Response to MarzAA</title>
        <description>Occurrence of an antibody response to MarzAA and whether it is inhibitory and cross-reactive to wild-type recombinant coagulation FVII (wt-rFVII) or wt-FVIIa</description>
        <time_frame>From time of first dose of MarzAA until date of first occurrence of clinical event, assessed up to End of Study. Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg SC Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of an Antibody Response to MarzAA</title>
          <description>Occurrence of an antibody response to MarzAA and whether it is inhibitory and cross-reactive to wild-type recombinant coagulation FVII (wt-rFVII) or wt-FVIIa</description>
          <units>participants with an occurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Clinical Thrombotic Event</title>
        <description>Occurrence of clinical thrombotic event not attributable to another cause</description>
        <time_frame>From the date of first dose of MarzAA until date of first occurrence of clinical event, assessed up to End of Study. Dosing period for each stage was approximately 3 days, with a maximum of approximately 8 weeks of dosing.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 MarzAA 18 µg/kg IV</title>
            <description>Single intravenous dose of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O2">
            <title>Stage 2 MarzAA 30 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O3">
            <title>Stage 3 MarzAA 45 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O4">
            <title>Stage 4 MarzAA 60 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O5">
            <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O6">
            <title>Stage 6 MarzAA 90 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O7">
            <title>Stage 7 MarzAA 120 µg/kg SC</title>
            <description>Single subcutaneous injection of MarzAA, coagulation factor VIIa variant</description>
          </group>
          <group group_id="O8">
            <title>Stage 8 2×60 µg/kg SC Q3H</title>
            <description>Two subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
          <group group_id="O9">
            <title>Stage 9 3×60 µg/kg Q3H</title>
            <description>Three subcutaneous injections of MarzAA, coagulation factor VIIa variant, every 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Clinical Thrombotic Event</title>
          <description>Occurrence of clinical thrombotic event not attributable to another cause</description>
          <units>participants with an occurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose.</time_frame>
      <desc>An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related.&#xD;
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug, without any judgment about causality. An AE could arise from any use of the drug (eg, off label use, use in combination with another drug) and from any route of administration, formulation, or dose, including an overdose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stage 1 MarzAA 18 µg/kg SC</title>
          <description>Single intravenous dose of MarzAA</description>
        </group>
        <group group_id="E2">
          <title>Stage 2 MarzAA 30 µg/kg SC</title>
          <description>Single subcutaneous injection of MarzAA</description>
        </group>
        <group group_id="E3">
          <title>Stage 3 MarzAA 45 µg/kg SC</title>
          <description>Single subcutaneous injection of MarzAA</description>
        </group>
        <group group_id="E4">
          <title>Stage 4 MarzAA 60 µg/kg SC</title>
          <description>Single subcutaneous injection of MarzAA</description>
        </group>
        <group group_id="E5">
          <title>Stage 5 MarzAA 2×30 µg/kg SC</title>
          <description>Two subcutaneous injections of MarzAA</description>
        </group>
        <group group_id="E6">
          <title>Stage 6 MarzAA 90 µg/kg SC</title>
          <description>Single subcutaneous injection of MarzAA</description>
        </group>
        <group group_id="E7">
          <title>Stage 7 MarzAA 120 µg/kg SC</title>
          <description>Single subcutaneous injection of MarzAA</description>
        </group>
        <group group_id="E8">
          <title>Stage 8 MarzAA 2×60 µg/kg SC Q3H</title>
          <description>Two subcutaneous injections of MarzAA every 3 hours</description>
        </group>
        <group group_id="E9">
          <title>Stage 9 MarzAA 3×60 µg/kg SC Q3H</title>
          <description>Three subcutaneous injections of MarzAA every 3 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Levy, Chief Medical Officer</name_or_title>
      <organization>Catalyst Biosciences</organization>
      <phone>+1.650.266.6871</phone>
      <email>hlevy@catbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

